
End of the vincristine/steroid pulse era in pediatric ALL?, “trial and error” with abatacept in GVHD, and hemorrhage risk with dasatinib therapy
Blood Podcast
00:00
Abadisept: A Trial and Error Candidate in Chronic GVHD
There was a decrease in expression of PD-1 on circulating CD4 positive T cells after abadisept therapy. However, there were no significant differences in pre or post-treatment levels of these cytokines and responders as compared to non-responders. There is an urgent need for a biomarker to predict response to different classes of agents used to treat chronic GVHD. Such markers could enable biology-driven treatment geared toward preventing the progression of the disease towards non-reversible changes.
Transcript
Play full episode